

Patient Name	:		Bill Date	:	
DOB/Age/Gender	:		Sample Collected	:	
Patient ID / UHID	:		Sample Received	:	
Referred By	:		Report Date	:	
Sample Type	:		Report Status	:	
Barcode No	:				

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY REPORT

CA 72.4 (Gastric Cancer Marker)

CA 72.4 (TAG-72) GASTRIC CANCER MARKER,SERUM Method : ECLIA	54.76	U/mL	<6.90
---	-------	------	-------

Result rechecked,Kindly correlate clinically .

Interpretation:

Note

1. This test is not recommended to screen Gastric cancer in the general population.
2. Sensitivity of monitoring Gastric carcinoma improves by combining CA 72.4 with CEA and CA 19.9 assays.
3. False negative/positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
4. This assay, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.
5. Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours after the last dose.

Clinical Use

- An aid in the management of Gastric cancer patients
- Monitor the course of disease and predict recurrence in patients with Gastric carcinoma
- Useful in detecting residual tumor

Gastric and Ovarian Cancer:

For gastric cancer, a diagnostic sensitivity of 33 % was reported for CA 72.4. Monitoring treatment and disease course in patients with gastric and ovarian cancer is the main indication for CA 72.4. After surgical intervention, CA 72.4 levels return to normal and remain within the normal range in cases where tumor tissue is no longer present.

A diagnostic sensitivity of 47.76 % has been reported in ovarian carcinoma. Especially for mucinous ovarian cancer, the diagnostic sensitivity of CA 72.4 is greater than that of CA 125. The Elecsys CA 72.4 assay utilizes the following two monoclonal antibodies to detect the mucin, TAG 72.

Increased Levels

- Gastric carcinoma
- Ovarian carcinoma
- Benign diseases - Pancreatitis, Cirrhosis, Pulmonary disease, Rheumatic conditions, Ovarian cysts, Benign breast disease, Benign gastrointestinal disorders



Sohini Sengupta

Dr. Sohini Sengupta
MD (Cl Biochemistry), DNB,
FNB (Lab Medicine)
Medical Laboratory Director
HOD (Biochemistry & Special Assays)

Booking Centre :- AFRICRYSTALCARE MEDICAL CENTRE, AFRICRYSTALCARE MEDICAL CENTRE
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.